Understanding Mucormycosis: Diagnosis, Treatment, and Distinguishing from Aspergillosis

February 25, 2024

Back
Featured image for “Understanding Mucormycosis: Diagnosis, Treatment, and Distinguishing from Aspergillosis”

Mucormycosis is an aggressive and highly fatal fungal infection that has been increasingly recognized in severely immunocompromised patients. This complex disease requires prompt diagnosis and treatment to improve outcomes. Interpreting imaging and distinguishing mucormycosis from lookalike infections like aspergillosis presents challenges for clinicians.

This article provides a practical overview of mucormycosis, with a focus on radiographic appearance, recommended therapies, and key differentiation points from aspergillosis to guide clinical decision making.

What is Mucormycosis?

Mucormycosis, also known as zygomycosis, is an angioinvasive fungal infection caused by fungi of the order Mucorales. Rhizopus, Mucor, and Lichtheimia (formerly Absidia) species are the most common causative organisms.

This rapidly progressive infection occurs almost exclusively in immunocompromised individuals with risk factors like:

  • Uncontrolled diabetes mellitus
  • Hematologic malignancies
  • Stem cell and solid organ transplantation
  • Long-term corticosteroid and immunosuppressive therapy
  • Severe malnutrition

Mucormycosis has also been reported as an emerging complication of COVID-19 infection.

The fungus enters the body through inhalation, ingestion, or direct skin inoculation. It then spreads via the blood vessels to various organs. The hyphae have a propensity to invade and thrombose arteries, causing tissue infarction and necrosis.

70

Rhinocerebral mucormycosis is the most common presentation, manifesting with sinusitis, orbital and brain involvement. Pulmonary mucormycosis generally occurs in patients with hematologic cancers or stem cell transplants. Gastrointestinal, cutaneous, and disseminated disease also occur.

Mucormycosis Pathophysiology and Virulence Factors

Mucormycosis pathogenesis relates to fungal virulence factors as well as alterations in the host immune response:

  • Angioinvasion: Mucorales hyphae directly penetrate the endothelial lining of blood vessels, allowing widespread dissemination but also resulting in vascular thrombosis and tissue necrosis.
  • Iron acquisition: The fungus expresses iron transporter genes for acquiring iron from host cells. Patients with elevated serum iron levels due to diabetes, chemotherapy, or blood transfusions are at heightened risk.
  • Spore size: Mucorales fungi produce asexual spores (sporangiospores) that are 5-50 μm. This size evades phagocytosis, preventing clearance by innate immune cells.
  • Rapid growth: The fungus grows rapidly, expanding 3-11 mm per day. This outpaces the immune system’s ability to wall it off, allowing angioinvasion and tissue destruction.
  • Toxin production: Some species secrete toxic metabolites that inhibit phagocyte and T-cell function.

In susceptible hosts with immune dysfunction, mucormycosis leverages these mechanisms for pathogenesis and life-threatening infection.

Clinical Manifestations of Mucormycosis

Mucormycosis can be an aggressive, fulminant infection with nonspecific symptoms initially. As the disease advances, symptoms relate to the site of involvement:

Rhinocerebral Mucormycosis

This is the most common form, accounting for one-third to half of cases. Early symptoms mimic sinusitis:

  • Facial pain, headache
  • Nasal discharge
  • Fevers
  • Sinus congestion

With orbital involvement, patients develop:

  • Eye swelling, redness
  • Blurred vision
  • Ophthalmoplegia (restricted eye movements)

Intracranial extension causes:

Advanced disease manifests with black eschars of necrotic tissue in the sinus/palate region.

Pulmonary Mucormycosis

Lung involvement generally occurs in the context of hematologic malignancy or stem cell transplant. Symptoms are nonspecific and mimic other infections:

  • Fever
  • Cough
  • Chest pain
  • Hemoptysis

Gastrointestinal Mucormycosis

This rare form presents with:

  • Abdominal pain
  • Gastrointestinal bleeding
  • Bowel perforation

Cutaneous Mucormycosis

This results from direct inoculation of skin through trauma, burns, or needle sticks. Local signs include:

  • Cellulitis
  • Tender skin nodules
  • Eschar formation

Disseminated mucormycosis with multiorgan failure can also occur in severely immunocompromised patients. Due to nonspecific symptoms and late diagnosis, overall mortality exceeds 50%.

Risk Factors and Susceptible Populations

Host factors that predispose patients to invasive mucormycosis include:

  • Diabetic ketoacidosis: Uncontrolled hyperglycemia causes impaired neutrophil and macrophage function. High serum iron levels also promote fungal growth. Diabetes accounts for 36-88% of cases.
  • Hematologic diseases: Leukemia, lymphoma, multiple myeloma and aplastic anemia are major risk factors. Disrupted immune surveillance and iron overload from RBC transfusions increase susceptibility.
  • Stem cell transplant: Graft versus host disease and its treatments suppress immunity for months after transplant. Pulmonary mucormycosis is an important complication.
  • Solid organ transplant: Immunosuppressive regimens put patients at risk. Renal failure requiring hemodialysis is an added risk factor.
  • Corticosteroids: High dose or chronic use impairs immune function, quadrupling the risk of invasive fungal infections. Up to 80% of patients have used steroids prior to diagnosis.
  • Trauma/burns: Breaches in skin integrity and impaired wound healing can enable direct inoculation of fungal spores into tissues.

Clinicians should monitor at-risk groups for early symptoms and promptly investigate for invasive fungal infections.

Diagnostic Evaluation of Mucormycosis

Definitive diagnosis requires identification of broad, ribbon-like hyphae with vascular invasion on histopathology. Obtaining tissue for culture and pathology poses challenges given the critical nature of affected patients.

Non-invasive diagnostic modalities serve a key role for initial diagnosis:

Imaging Studies

Radiologic imaging with CT and MRI detects characteristic signs of mucormycosis:

  • Nasal endoscopy often shows black eschars from necrotic turbinates early in sinus disease.
  • CT reveals sinus opacification, mucosal thickening with hyperdense foci, and bony erosion indicating invasive, angioinvasive disease. The orbital and intracranial compartments may also be involved.
  • The “reverse halo sign” on CT describes a rounded consolidation encircled by ground glass opacity. This finding is strongly associated with pulmonary mucormycosis.
  • MRI offers superb soft tissue delineation for sinus, orbit and brain involvement using DWI, contrast enhancement and fat saturated sequences.

Imaging cannot confirm mucormycosis histologically but strongly supports invasive fungal infection. Tracking disease extent guides surgical approaches.

55

Laboratory Findings

  • Complete blood count: Leukocytosis or cytopenia, anemia
  • Metabolic panel: Ketoacidosis, renal failure
  • Elevated ESR and CRP indicate severe inflammation
  • Fungal smear and culture isolating Mucorales species

Together with imaging, microbiology and clinical context, a presumptive diagnosis can inform urgent antifungal treatment.

Pathology and Histologic Features

Obtaining infected tissue samples for microscopic analysis and fungal culture allows definitive diagnosis but may not be feasible in unstable patients:

  • Fungal hyphae have irregular, ribbon-like 5-20 μm diameter filaments with few septations. Wide angle branching occurs sporadically (45-90 degrees).
  • Vascular invasion with arterial thrombosis. Fungal proliferation continues within the vessel wall.
  • Necrotizing inflammation. Widespread necrosis manifests microscopically as ghosts of hyphae due to loss of staining in dead fungus.
  • Perineural invasion is common. Fungal proliferation along nerve sheaths can cause cranial neuropathies.

Tissue specimens from infected sinuses, lung nodules, or skin lesions are subjected to frozen section analysis. KOH stain helps visualize fungal elements for rapid diagnosis to guide surgery. Formal surgical pathology and fungal culture provide confirmation.

Treatment of Mucormycosis

Aggressive medical and surgical therapy is required, with antifungal therapy alone having little efficacy. A multidisciplinary approach offers the best chance of survival.

First-line Treatment

Liposomal amphotericin B is the first-line antifungal agent, given daily at high doses (≥5 mg/kg) to stabilize critically ill patients. This formulation achieves higher plasma levels with less toxicity compared to conventional amphotericin B.

Patients often require prolonged IV therapy for 6-8 weeks or longer depending on disease severity, immune reconstitution, and clinical response.

Second-line Treatment

Posaconazole is an oral azole agent used as step down oral therapy for stable patients to complete treatment course. Drug interactions must be monitored.

Isavuconazole is a newer IV/oral azole active against Mucorales molds. It offers an alternative to posaconazole.

Adjunctive Therapies

  • Iron chelation therapy with deferasirox limits iron availability for fungal growth.
  • Therapeutic drug monitoring ensures adequate serum levels of antifungal agents
  • Granulocyte transfusions provide immune cells to fight infection
  • Hyperbaric oxygen enhances neutrophil killing power
  • Cytokines like interferon-γ stimulate the immune response against the fungus.

Surgical Intervention

In addition to antifungal medications, repeated debridement and resection of infected/necrotic tissue is critical. This eliminates fungal burden and prevents further angioinvasion.

Common surgeries include:

  • Endoscopic sinus debridement
  • Orbital exenteration
  • Palatal/maxillectomy procedures
  • Lobectomy for isolated lung nodules

With early diagnosis and multifaceted treatment, survival rates now approach 70%. Delays in therapy lead to higher mortality.

How Mucormycosis Differs from Aspergillosis

Aspergillosis is another serious fungal infection in immunocompromised patients that can have overlapping features with mucormycosis. Distinguishing these entities has important implications for accurate diagnosis, treatment, and prognosis.

Causative Organisms

  • Mucormycosis is caused by molds of the order Mucorales, like Rhizopus, Mucor, Rhizomucor, and Lichtheimia (formerly Absidia) species.
  • Aspergillosis is most often caused by Aspergillus fumigatus or Aspergillus flavus. These are molds belonging to the order Eurotiales.

Host Risk Factors

  • Mucormycosis mainly afflicts patients with poorly controlled diabetes, iron overload states, or allogeneic stem cell transplants.
  • Aspergillosis predominantly affects patients with hematologic cancers, solid organ transplants, chronic lung diseases and less commonly, solid tumors.

Pathophysiologic Characteristics

Mucormycosis exhibits more angioinvasive and rapidly destructive disease. Key differences include:

  • Angioinvasion: Mucorales hyphae directly penetrate vessels, causing extensive thrombosis and tissue necrosis. Aspergillus less commonly invades arteries.
  • Iron acquisition: Mucorales expresses genes enabling iron uptake from host cells to supply growth. Aspergillus lacks this mechanism.
  • Growth rate: Mucorales grow extremely rapidly, expanding many millimeters per day. Aspergillus growth is far more limited.
  • Spore size: Mucorales spores are too large to be phagocytosed, evading immune cells. Aspergillus conidia can be cleared.

Imaging Appearance

  • The reverse halo sign on CT is fairly specific for pulmonary mucormycosis. For aspergillosis, findings are more nonspecific including nodules, masses, or cavities.
  • Bony erosion or destruction indicates the invasive, rapidly progressive nature of mucormycosis. Aspergillus does not destroy bone.
  • Both entities can manifest mucosal plaque or hyperdensity in the sinuses as well as turbinate necrosis. However this occurs earlier with mucormycosis.

Required Therapy

The cornerstone of mucormycosis treatment involves both aggressive surgical debridement/resection of infected foci, as well as high dose, extended duration liposomal amphotericin B. Mortality exceeds 80% with antifungals alone.

Aspergillosis can often be effectively treated with voriconazole without surgery, although some patients may require surgical drainage.

Prognosis

Despite modern treatments, mucormycosis still has a mortality rate of 30-70%. Outcomes strongly depend on rapid diagnosis, reversal of underlying risk factors like diabetic ketoacidosis, surgical debridement, and appropriately lengthy antifungal therapy.

By comparison, overall mortality rates for invasive aspergillosis range from 30-95% depending on host factors and severity of disease at presentation. Voriconazole has markedly improved outcomes.

Staying abreast of delicate distinguishing features allows providers to pursue mucormycosis-directed therapy when appropriate to maximize patient survival.

71

Frequently Asked Questions

How do you diagnose mucormycosis?

Definitive diagnosis requires culture or histopathology demonstrating broad, ribbon-like hyphae with vascular invasion. Presumptive diagnosis relies on host risk factors, clinical context, imaging studies suggesting invasive disease and possible fungal elements on smear. Tissue biopsy or debridement should be urgently pursued for confirmation.

What scan is used to detect mucormycosis?

CT imaging plays a vital role in detecting sinus disease and lung nodules suspicious for mucormycosis. MRI offers further characterization of orbital and intracranial disease. The reverse halo sign on CT is strongly suggestive of angioinvasive pulmonary infection. Scan findings guide biopsy targets.

How do you treat mucormycosis?

Multimodal therapy is essential for survivability. High dose liposomal amphotericin B serves as first line antifungal treatment. Extensive surgical resection and debridement of infected tissue is also critical. Underlying risk factors like diabetic ketoacidosis require correction. With early, aggressive intervention using all modalities, survival is now up to 70%.

What is the difference between mucormycosis and aspergillosis?

These two devastating fungal infections share risk groups but have key differences. Mucormycosis exhibits greater angioinvasion, more rapid growth overwhelming host defenses, larger spores avoiding phagocytosis and unique expression of iron transporter genes. The reverse halo lesion favors mucormycosis while aspergillosis has more nonspecific imaging. Multidisciplinary mucormycosis therapy improves outcomes.

What is the most common site affected by mucormycosis?

Rhinocerebral and pulmonary disease are the two most common presentations. Rhinocerebral mucormycosis starts with sinusitis then extends to orbit and brain in one-third of patients. Pulmonary disease affects immunocompromised hosts, especially leukemia and transplant patients. Gastrointestinal, cutaneous and disseminated disease occur less often.

Conclusion and Key Takeaways

  • Mucormycosis is an aggressive, angioinvasive fungal infection increasingly seen in susceptible immunocompromised individuals. Rhinocerebral and pulmonary disease predominate.
  • Diabetic ketoacidosis, hematologic diseases, and allogenic stem cell transplantation comprise top host risk factors. Trauma and burns can also introduce infection.
  • Characteristic CT and MRI findings like the reverse halo sign, mucosal plaque, or bony erosion indicate rapid, invasive spread. Biopsy confirms diagnosis.
  • Empiric high dose liposomal amphotericin and radical debridement of infected tissue offer the best odds of survival. Anti-fungal therapy alone is often ineffective.
  • Distinguishing mucormycosis from aspergillosis guides appropriate diagnosis and treatment decisions. Appreciating subtle differences in risk factors, pathophysiology, imaging and required therapies optimizes outcomes for invasive fungal disease.
  • Despite aggressive measures, mucormycosis still carries high mortality often exceeding 50%. A low threshold for investigation allows rapid multidisciplinary intervention to give patients their best chance.
Rate this post

Related articles



Image
Image

MIRARI®
Cold Plasma System

The world's first handheld cold plasma device

Learn More


Made in USA

Image